To investigate how MPAS derived from clinical tumor specimens related to MEK1/2 inhibitor sensitivity across tissue types, we examined the correlation between the median MPAS of tumor specimens from each indication (Fig. 2a) with the median cobimetinib sensitivity (i.e., MV) of cancer cell lines derived from corresponding tissue types (Fig. 2b, Materials and methods, y axis denotes 1-MV). The gene discussed is MAP2K1; the disease is cancer.